» Articles » PMID: 8294000

Cloning of the CDNA Encoding Human Brain Trypsinogen and Characterization of Its Product

Overview
Journal Gene
Specialty Molecular Biology
Date 1993 Dec 22
PMID 8294000
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

We designed degenerated oligodeoxyribonucleotide primers derived from amino acid (aa) sequences of the highly conserved active sites of mammalian serine proteases (SPs). These primers were used to selectively amplify, in polymerase chain reactions (PCRs), cDNA fragments coding for a SP. We used poly(A)+RNA from human brain to obtain cDNA fragments and amplified one cDNA encoding a novel SP. The full-length nucleotide (nt) sequence was identified by PCR and screening a genomic library in order to obtain the 5'-region. The deduced as sequence shows a high degree of homology to trypsinogens, except for the first exon. In addition to this brain-specific trypsinogen, there exists a variant of the cDNA in pancreas, differing only in the nt sequence of the first exon. An active form of the trypsin was synthesized in vitro and purified by affinity chromatography using soybean trypsin inhibitor (STI) agarose to demonstrate the trypsin-specific interaction with a naturally occurring inhibitor of trypsins.

Citing Articles

Protease-activated receptors in health and disease.

Peach C, Edgington-Mitchell L, Bunnett N, Schmidt B Physiol Rev. 2022; 103(1):717-785.

PMID: 35901239 PMC: 9662810. DOI: 10.1152/physrev.00044.2021.


CpG Site-Specific Methylation-Modulated Divergent Expression of Transcript Variants Facilitates Nongenetic Intratumor Heterogeneity in Human Hepatocellular Carcinoma.

Lin S, Xu H, Pang M, Zhou X, Pan Y, Zhang L Front Oncol. 2022; 12:831268.

PMID: 35480112 PMC: 9035874. DOI: 10.3389/fonc.2022.831268.


Epigenetic silencing of PRSS3 provides growth and metastasis advantage for human hepatocellular carcinoma.

Lin B, Zhou X, Lin S, Wang X, Zhang M, Cao B J Mol Med (Berl). 2017; 95(11):1237-1249.

PMID: 28844099 PMC: 8171496. DOI: 10.1007/s00109-017-1578-5.


Combinatorial protein engineering of proteolytically resistant mesotrypsin inhibitors as candidates for cancer therapy.

Cohen I, Kayode O, Hockla A, Sankaran B, Radisky D, Radisky E Biochem J. 2016; 473(10):1329-41.

PMID: 26957636 PMC: 4898653. DOI: 10.1042/BJ20151410.


Trypsinogen 4 boosts tumor endothelial cells migration through proteolysis of tissue factor pathway inhibitor-2.

Ghilardi C, Silini A, Figini S, Anastasia A, Lupi M, Fruscio R Oncotarget. 2015; 6(29):28389-400.

PMID: 26318044 PMC: 4695067. DOI: 10.18632/oncotarget.4949.